Valion Bio, Inc.(VBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.8M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
VBIO Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Valion Bio, Inc. (VBIO), a Healthcare sector company. VBIO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.8m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Valion Bio, Inc. reports net income of $-7.1M, free cash flow of $-5.3M. VBIO trades on the Nasdaq exchange and files with the SEC under CIK 1787740. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Valion Bio, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-7.1M
Free Cash Flow
Q2 2026
$-5.3M
Get alerted when VBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Valion Bio, Inc. including:
More Healthcare Companies
View all Healthcare →Put VBIO on your watchlist
Track score changes the day Valion Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VBIO a good stock to buy?
13F Pro's AI-powered analysis of Valion Bio, Inc. (VBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VBIO are available on the VBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VBIO is classified as a small company.
Which hedge funds own VBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Valion Bio, Inc.'s investment landscape.